The microbiome therapies pipeline features 260 drugs under evaluation across different(RootsAnalysis

Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.

To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments:
 Type of Product Manufactured
 Active Pharmaceutical Ingredients (APIs)
 Finish Drug Formulations (FDFs)

 Type of Type of Formulation
 Solid Formulations
 Oral Liquids
 Injectables
 Others

 Scale of Operation
 Clinical
 Commercial

 Company Size
 Small-sized
 Mid-sized
 Large

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific and Rest of the World

The Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, report features the following companies, which we identified to be key players in this domain:
 Bristol Myers Squibb
 GlaxoSmithKline
 Incyte
 Novartis
 Trillium Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Profiles

6. Regional Capability Analysis

7. Likely Partner Analysis

8. Clinical Trial Analysis

9. Capacity Analysis

10. Demand Analysis

11. Make versus Buy Decision Making Framework

12. Microbiome related initiatives of Big Pharmaceutical Players

13. Market Forecast

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Leave a Reply

Your email address will not be published. Required fields are marked *